New combo therapy shows promise for rare liver disease
NCT ID NCT05239468
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tested whether adding the drug bezafibrate to another drug, obeticholic acid, helps people with primary biliary cholangitis (PBC), a chronic liver disease. 72 adults with PBC took one or both drugs for 12 weeks. The main goal was to see if the combination improved liver enzyme levels, which are markers of liver damage. The study has finished, and results will show if this approach is safe and effective for managing PBC.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
-
Beth Israel Deaconess Medical Center Harvard Liver Research Center
Boston, Massachusetts, 02215, United States
-
DIM Clinical Privada
Ramos Mejía, Buenos Aires, Argentina
-
Facey Medical Group
Mission Hills, California, 91345, United States
-
Gastro One
Cordova, Tennessee, 38018, United States
-
Gastrointestinal Associates of Northeast Tennessee
Johnson City, Tennessee, 37604, United States
-
Hospital Italiano La Plata
La Plata, Buenos Aires, Argentina
-
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
-
Hospital Provincial del Centenario
Rosario, Argentina
-
Hospital Universitario Austral
Pilar, Argentina
-
Houston Methodist Cancer Center
Houston, Texas, 77030-2717, United States
-
Loyola University Medical Center
Maywood, Illinois, 60459, United States
-
Methodist Clinical Research Institute (CRI)
Dallas, Texas, 75203, United States
-
NYU Langone Medical Center
New York, New York, 10016-6402, United States
-
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
-
Pacific Gastroenterology Associates
Vancouver, British Columbia, V6Z 2K5, Canada
-
Piedmont Atlanta Hospital
Atlanta, Georgia, 30309, United States
-
Schiff Center for Liver Diseases / University of Miami
Miami, Florida, 33136, United States
-
Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado
Coronado, California, 92118, United States
-
Tampa General Medical Group
Tampa, Florida, 33606, United States
-
The Northern Alberta Clinical Trials and Research Centre
Edmonton, Alberta, T6G 287, Canada
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Montreal
Montreal, Quebec, Canada
-
Wake Endoscopy Center
Raleigh, North Carolina, 27607, United States
Conditions
Explore the condition pages connected to this study.